|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
ATE442862T2
(de)
*
|
2000-10-12 |
2009-10-15 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
TWI255272B
(en)
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
CN1292655C
(zh)
*
|
2001-11-08 |
2007-01-03 |
蛋白质设计实验室股份有限公司 |
IgG抗体稳定的液态药物制剂
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20040002451A1
(en)
*
|
2002-06-20 |
2004-01-01 |
Bruce Kerwin |
Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
|
|
EP1551875A4
(en)
*
|
2002-06-21 |
2006-06-28 |
Biogen Idec Inc |
TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
*
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
AU2003293543A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
|
US20040208870A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
|
|
CA2517310C
(en)
|
2003-02-28 |
2015-11-24 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized protein-containing formulations comprising a poloxamer
|
|
US20050158303A1
(en)
*
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
|
RU2332986C2
(ru)
|
2003-04-04 |
2008-09-10 |
Дженентек, Инк. |
Высококонцентрированные композиции антител и белков
|
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
|
CA2544532C
(en)
*
|
2003-11-28 |
2015-06-16 |
Micromet Ag |
Compositions comprising polypeptides
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
NZ548702A
(en)
*
|
2004-01-09 |
2009-06-26 |
Pfizer |
Antibodies to MAdCAM
|
|
US20060008415A1
(en)
*
|
2004-06-25 |
2006-01-12 |
Protein Design Labs, Inc. |
Stable liquid and lyophilized formulation of proteins
|
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
CA2590337C
(en)
|
2004-12-15 |
2017-07-11 |
Neuralab Limited |
Humanized amyloid beta antibodies for use in improving cognition
|
|
WO2006066049A2
(en)
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
GT200600033A
(es)
*
|
2005-01-28 |
2006-10-25 |
|
Formulaciones liquidas estabilizadas de polipeptido
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
TW200719913A
(en)
*
|
2005-03-08 |
2007-06-01 |
Pharmacia & Upjohn Co Llc |
Anti-madcam antibody compositions
|
|
LT2586459T
(lt)
|
2005-03-25 |
2017-09-25 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonisto kompozicijos
|
|
US8858935B2
(en)
*
|
2005-05-19 |
2014-10-14 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
EP3673919A1
(en)
|
2005-06-14 |
2020-07-01 |
Amgen Inc. |
Self-buffering protein formulations
|
|
JP2008546805A
(ja)
*
|
2005-06-23 |
2008-12-25 |
メディミューン，エルエルシー |
最適な凝集および断片化プロフィールを有する抗体製剤
|
|
MX2008001068A
(es)
*
|
2005-07-29 |
2008-03-19 |
Amgen Inc |
Formulacion que inhibe la agregacion de proteina.
|
|
MX336033B
(es)
*
|
2005-08-03 |
2016-01-07 |
Immunogen Inc |
Formulaciones de inmunoconjugado.
|
|
CA2625815A1
(en)
*
|
2005-09-12 |
2007-03-22 |
Novimmune S.A. |
Anti-cd3 antibody formulations
|
|
KR101105871B1
(ko)
*
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
|
EP1951757B1
(en)
|
2005-10-06 |
2014-05-14 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
WO2007076062A2
(en)
*
|
2005-12-21 |
2007-07-05 |
Wyeth |
Protein formulations with reduced viscosity and uses thereof
|
|
CA2637726C
(en)
*
|
2006-01-25 |
2014-04-15 |
Taro Pharmaceuticals North America, Inc. |
Anti-histamine compositions and use thereof
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
|
CN101421411B
(zh)
|
2006-04-13 |
2015-06-03 |
中外制药株式会社 |
牛磺酸转运蛋白基因
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
KR101317235B1
(ko)
|
2006-04-21 |
2013-10-15 |
조마 테크놀로지 리미티드 |
길항제 항-ｃｄ40 항체 제약 조성물
|
|
AU2014268186C1
(en)
*
|
2006-04-26 |
2017-12-07 |
Wyeth Llc |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
AU2016204760A1
(en)
*
|
2006-04-26 |
2016-07-28 |
Wyeth Llc |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
CN104434770A
(zh)
|
2006-06-16 |
2015-03-25 |
瑞泽恩制药公司 |
适合玻璃体内施用的vegf拮抗剂的制剂
|
|
AU2012200284B2
(en)
*
|
2006-10-06 |
2014-03-06 |
Amgen Inc. |
Stable Antibody Formulations
|
|
EP2081553B1
(en)
*
|
2006-10-06 |
2020-08-12 |
Amgen Inc. |
Stable antibody formulations
|
|
ES2925992T3
(es)
*
|
2006-10-20 |
2022-10-20 |
Amgen Inc |
Formulaciones estables de polipéptidos
|
|
MX2009006594A
(es)
*
|
2006-12-21 |
2009-08-12 |
Amgen Inc |
Formulaciones de ph regulado y estables que contienen polipeptidos.
|
|
JP5635260B2
(ja)
|
2007-03-15 |
2014-12-03 |
中外製薬株式会社 |
ポリペプチドの製造方法
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
WO2009009406A1
(en)
*
|
2007-07-06 |
2009-01-15 |
Smithkline Beecham Corporation |
Antibody formulations
|
|
PT2182983E
(pt)
|
2007-07-27 |
2014-09-01 |
Janssen Alzheimer Immunotherap |
Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
|
|
MX2010001319A
(es)
|
2007-08-07 |
2010-06-01 |
Chugai Pharmaceutical Co Ltd |
Metodo para producir proteinas heterogeneas.
|
|
CN101874042B9
(zh)
|
2007-09-26 |
2019-01-01 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
|
PE20140132A1
(es)
|
2007-09-26 |
2014-02-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-receptor de il-6
|
|
TWI464262B
(zh)
|
2007-09-26 |
2014-12-11 |
中外製藥股份有限公司 |
抗體固定區的變異
|
|
EP2194126B1
(en)
|
2007-10-15 |
2014-01-15 |
Chugai Seiyaku Kabushiki Kaisha |
Method of constructing cells with high productivity of foreign protein
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
JP5337044B2
(ja)
|
2007-10-24 |
2013-11-06 |
中外製薬株式会社 |
異種タンパク質製造のための細胞及びそれを用いた製造方法
|
|
EP3381445B1
(en)
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
EP2240156A2
(en)
*
|
2007-12-28 |
2010-10-20 |
BioInvent International AB |
Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
|
|
EP2328607A1
(en)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
|
JP5524967B2
(ja)
*
|
2008-09-19 |
2014-06-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
新規抗体処方物
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
AU2009319856A1
(en)
*
|
2008-11-28 |
2010-06-03 |
Abbvie Inc. |
Stable antibody compositions and methods for stabilizing same
|
|
EP2196476A1
(en)
*
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
WO2010100135A1
(en)
|
2009-03-05 |
2010-09-10 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
AR076640A1
(es)
*
|
2009-03-06 |
2011-06-29 |
Genentech Inc |
Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
|
|
WO2010115728A2
(en)
*
|
2009-03-30 |
2010-10-14 |
F. Hoffmann-La Roche Ag |
A method for avoiding glass fogging
|
|
EP2423309B1
(en)
|
2009-04-22 |
2018-01-03 |
Chugai Seiyaku Kabushiki Kaisha |
A method for producing a cell capable of high-yield production of heteroproteins
|
|
US20100278822A1
(en)
*
|
2009-05-04 |
2010-11-04 |
Abbott Biotechnology, Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
WO2011008770A2
(en)
*
|
2009-07-14 |
2011-01-20 |
Biogen Idec Ma Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
|
CA2726232A1
(en)
*
|
2009-07-16 |
2010-08-12 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
|
BR112012004510A2
(pt)
|
2009-08-31 |
2016-11-16 |
Abbott Biotherapeutics Corp |
uso de uma população de célula nk imunorreguladora para monitar a eficácia dos anticorpos anti-il-2r em pacientes de esclerose múltipla.
|
|
LT2805731T
(lt)
*
|
2009-09-03 |
2019-02-11 |
Ablynx N.V. |
Stabilios polipeptidų kompozicijos ir jų panaudojimas
|
|
WO2011028961A2
(en)
*
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Anti-botulism antibody coformulations
|
|
EP2473191B1
(en)
*
|
2009-09-04 |
2017-08-23 |
XOMA Technology Ltd. |
Antibody coformulations
|
|
BR112012011463A2
(pt)
|
2009-10-30 |
2017-05-02 |
Abbott Biotherapeutics Corp |
uso de populações imunorregulatórias de célula nk para prognosticar a eficácia de anticorpos anti-il-2r em pacientes com esclerose múltipla.
|
|
WO2011080209A2
(en)
*
|
2009-12-29 |
2011-07-07 |
F. Hoffmann-La Roche Ag |
Novel antibody formulation
|
|
AU2011204349C1
(en)
|
2010-01-06 |
2017-02-16 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein binding proteins
|
|
US20120294866A1
(en)
*
|
2010-01-19 |
2012-11-22 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for proteins
|
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
|
CA2976671C
(en)
|
2010-03-01 |
2021-01-12 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
|
CA2794929C
(en)
*
|
2010-03-01 |
2018-06-05 |
Progenics Pharmaceuticals, Inc. |
Concentrated protein formulations and uses thereof
|
|
US9095567B2
(en)
|
2010-06-04 |
2015-08-04 |
Wyeth Llc |
Vaccine formulations
|
|
FR2961107B1
(fr)
*
|
2010-06-15 |
2012-07-27 |
Lab Francais Du Fractionnement |
Composition d'immunoglobulines humaines stabilisee
|
|
CA2810734A1
(en)
*
|
2010-09-17 |
2012-03-22 |
Baxter International Inc. |
Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph
|
|
JO3400B1
(ar)
|
2010-09-30 |
2019-10-20 |
Ferring Bv |
مركب صيدلاني من كاربيتوسين
|
|
PL2635601T3
(pl)
|
2010-11-04 |
2017-02-28 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty-il-23
|
|
MX344727B
(es)
|
2010-11-11 |
2017-01-05 |
Abbvie Biotechnology Ltd |
Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
|
|
EP2471554A1
(en)
*
|
2010-12-28 |
2012-07-04 |
Hexal AG |
Pharmaceutical formulation comprising a biopharmaceutical drug
|
|
WO2012094587A1
(en)
|
2011-01-06 |
2012-07-12 |
Dyax Corp. |
Plasma kallikrein binding proteins
|
|
JP2014503555A
(ja)
|
2011-01-13 |
2014-02-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
|
|
PL2697369T3
(pl)
|
2011-03-25 |
2018-12-31 |
F.Hoffmann-La Roche Ag |
Nowe sposoby oczyszczania białek
|
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
|
JP2014522843A
(ja)
*
|
2011-06-30 |
2014-09-08 |
ジェネンテック， インコーポレイテッド |
抗ｃ−ｍｅｔ抗体製剤
|
|
US9089529B2
(en)
|
2011-10-25 |
2015-07-28 |
Prothena Therapeutics Limited |
Antibody formulations and methods
|
|
MX370199B
(es)
*
|
2012-02-16 |
2019-12-05 |
Santarus Inc |
Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
|
|
PL3326649T3
(pl)
*
|
2012-05-03 |
2022-04-25 |
Boehringer Ingelheim International Gmbh |
Przeciwciała anty-il-23p19
|
|
NZ701915A
(en)
|
2012-05-18 |
2016-11-25 |
Genentech Inc |
High-concentration monoclonal antibody formulations
|
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
|
HK1209343A1
(en)
*
|
2012-07-09 |
2016-04-01 |
Coherus Biosciences, Inc. |
Etanercept formulations exhibiting marked reduction in sub-visible particles
|
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
|
LT2892550T
(lt)
|
2012-09-07 |
2020-04-10 |
Coherus Biosciences, Inc. |
Stabilios adalimumabo vandeninės kompozicijos
|
|
EP2727602A1
(en)
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
KR20150132473A
(ko)
|
2013-03-15 |
2015-11-25 |
다이액스 코포레이션 |
항-혈장 칼리크레인 항체
|
|
CN105377892A
(zh)
|
2013-03-15 |
2016-03-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
|
HK1220212A1
(zh)
|
2013-03-15 |
2017-04-28 |
Abbvie Biotechnology Ltd |
抗cd25抗体及其用途
|
|
WO2014141152A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Low concentration antibody formulations
|
|
CN103217525B
(zh)
*
|
2013-03-21 |
2015-04-29 |
上海执诚生物科技股份有限公司 |
一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
|
|
KR20140119396A
(ko)
|
2013-03-29 |
2014-10-10 |
삼성전자주식회사 |
단백질 약물의 액상 제형
|
|
BR112016003293A8
(pt)
|
2013-08-30 |
2022-08-16 |
Takeda Gmbh |
Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos
|
|
PT3071237T
(pt)
|
2013-11-21 |
2024-08-26 |
Genmab As |
Formulação liofilizada de conjugados anticorpo-fármaco
|
|
ES2856076T3
(es)
|
2014-01-21 |
2021-09-27 |
Takeda Pharmaceuticals Co |
Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario
|
|
US10428158B2
(en)
|
2014-03-27 |
2019-10-01 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
|
BR112016025126B1
(pt)
*
|
2014-05-07 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
|
|
TWI694836B
(zh)
*
|
2014-05-16 |
2020-06-01 |
英商葛蘭素史克智慧財產管理有限公司 |
抗體調配物
|
|
US10478498B2
(en)
|
2014-06-20 |
2019-11-19 |
Reform Biologics, Llc |
Excipient compounds for biopolymer formulations
|
|
US11357857B2
(en)
|
2014-06-20 |
2022-06-14 |
Comera Life Sciences, Inc. |
Excipient compounds for protein processing
|
|
US20160074515A1
(en)
|
2014-06-20 |
2016-03-17 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
|
US10588980B2
(en)
|
2014-06-23 |
2020-03-17 |
Novartis Ag |
Fatty acids and their use in conjugation to biomolecules
|
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
|
EP3851445A1
(en)
|
2014-06-23 |
2021-07-21 |
Novartis AG |
Site specific protein modifications
|
|
EP3708679A1
(en)
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
|
CA2959629C
(en)
|
2014-09-03 |
2023-10-31 |
Boehringer Ingelheim International Gmbh |
Compound targeting il-23a and tnf-alpha and uses thereof
|
|
TN2017000148A1
(en)
|
2014-10-24 |
2018-10-19 |
Merck Sharp & Dohme |
Co-agonists of the glucagon and glp-1 receptors
|
|
SI3215530T1
(sl)
|
2014-11-07 |
2020-02-28 |
Sesen Bio, Inc. |
Izboljšana protitelesa IL-6
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
CN107406490A
(zh)
|
2015-01-23 |
2017-11-28 |
诺华股份有限公司 |
具有改善的半衰期的合成apelin脂肪酸缀合物
|
|
EP4670787A2
(en)
|
2015-02-04 |
2025-12-31 |
Boehringer Ingelheim International GmbH |
METHODS OF TREATMENT FOR INFLAMMATORY DISEASES
|
|
US11091543B2
(en)
|
2015-05-07 |
2021-08-17 |
Swedish Orphan Biovitrum Ag |
Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
|
|
EA037532B1
(ru)
|
2015-05-07 |
2021-04-08 |
Новиммун Са |
Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
EP4209499B1
(en)
|
2015-08-13 |
2024-08-07 |
Amgen Inc. |
Charged depth filtration of antigen-binding proteins
|
|
US11229702B1
(en)
|
2015-10-28 |
2022-01-25 |
Coherus Biosciences, Inc. |
High concentration formulations of adalimumab
|
|
FI3384049T3
(fi)
|
2015-12-03 |
2023-09-25 |
Regeneron Pharma |
Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
|
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
|
IL311156A
(en)
|
2015-12-11 |
2024-04-01 |
Takeda Pharmaceuticals Co |
Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
|
|
EP3393494A1
(en)
|
2015-12-22 |
2018-10-31 |
Novartis Ag |
Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
|
ES2983242T3
(es)
|
2016-01-13 |
2024-10-22 |
Genmab As |
Formulación para anticuerpo y conjugado de fármaco del mismo
|
|
AR107708A1
(es)
*
|
2016-02-23 |
2018-05-23 |
Eleven Biotherapeutics Inc |
Formulaciones de antagonista de il-6 y sus usos
|
|
US11071782B2
(en)
|
2016-04-20 |
2021-07-27 |
Coherus Biosciences, Inc. |
Method of filling a container with no headspace
|
|
WO2018027195A1
(en)
*
|
2016-08-05 |
2018-02-08 |
Abbvie Biotherapeutics Inc. |
Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
|
|
WO2018075818A1
(en)
|
2016-10-21 |
2018-04-26 |
Amgen Inc. |
Pharmaceutical formulations and methods of making the same
|
|
EA201990930A1
(ru)
*
|
2016-10-24 |
2019-11-29 |
|
Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний
|
|
KR20180046888A
(ko)
|
2016-10-28 |
2018-05-09 |
(주)셀트리온 |
안정한 약제학적 제제
|
|
EP3824906A1
(en)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
US11608357B2
(en)
|
2018-08-28 |
2023-03-21 |
Arecor Limited |
Stabilized antibody protein solutions
|
|
GB201703062D0
(en)
*
|
2017-02-24 |
2017-04-12 |
Arecor Ltd |
Stabilized antibody protein solutions
|
|
WO2018156367A1
(en)
*
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
|
WO2018156180A1
(en)
|
2017-02-24 |
2018-08-30 |
Kindred Biosciences, Inc. |
Anti-il31 antibodies for veterinary use
|
|
TWI761453B
(zh)
*
|
2017-03-01 |
2022-04-21 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
|
EP3372241A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
EP3372242A1
(en)
|
2017-03-06 |
2018-09-12 |
Ares Trading S.A. |
Liquid pharmaceutical composition
|
|
US20200093927A1
(en)
*
|
2017-03-31 |
2020-03-26 |
Meiji Seika Pharma Co., Ltd. |
Aqueous formulation and in-syringe aqueous formulation, and antibody protein deaggregation agent and antibody protein deaggregation method
|
|
WO2018193471A1
(en)
*
|
2017-04-18 |
2018-10-25 |
Dr. Reddy's Laboratories Limited |
Stable liquid pharmaceutical composition
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
BR112019022873A8
(pt)
|
2017-05-02 |
2023-04-11 |
Merck Sharp & Dohme |
Formulação, e, vaso ou dispositivo de injeção.
|
|
WO2018210230A1
(zh)
*
|
2017-05-16 |
2018-11-22 |
江苏恒瑞医药股份有限公司 |
一种pd-l1抗体药物组合物及其用途
|
|
GB201708655D0
(en)
|
2017-05-31 |
2017-07-12 |
Ucb Biopharma Sprl |
Cell culture methods
|
|
MA48241A1
(fr)
|
2017-07-14 |
2021-03-31 |
Pfizer |
Anticorps dirigés contre madcam
|
|
BR112020004325A2
(pt)
|
2017-09-05 |
2020-10-06 |
Merck Sharp & Dohme Corp. |
compostos para reduzir a viscosidade de formulações biológicas
|
|
WO2019055902A1
(en)
*
|
2017-09-18 |
2019-03-21 |
Amgen Inc. |
FUSION PROTEIN FORMULATIONS VEGFR-FC
|
|
ES2927049T3
(es)
|
2017-11-30 |
2022-11-02 |
Regeneron Pharma |
Uso de un antagonista del VEGF para tratar trastornos oculares angiogénicos
|
|
IL307483A
(en)
|
2017-12-22 |
2023-12-01 |
Novartis Ag |
Methods for treating metabolic disorders with FGF21 variants
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
UA130009C2
(uk)
|
2018-05-07 |
2025-10-15 |
Генмаб А/С |
Спосіб лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора і лікарського засобу
|
|
PT4364724T
(pt)
|
2018-05-10 |
2025-12-16 |
Regeneron Pharma |
Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
KR20210105872A
(ko)
*
|
2018-07-20 |
2021-08-27 |
모멘타 파머슈티컬스 인코포레이티드 |
Fcrn 항체 조성물 및 이의 사용 방법
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
CN113316458B
(zh)
|
2018-11-07 |
2024-08-02 |
默沙东有限责任公司 |
抗lag3抗体和抗pd-1抗体的共制剂
|
|
US20220025344A1
(en)
|
2018-11-26 |
2022-01-27 |
Novartis Ag |
Lpl-gpihbp1 fusion polypeptides
|
|
US20230287122A1
(en)
*
|
2018-11-29 |
2023-09-14 |
Harbour Biomed Therapeutics Limited |
Anti-pd-l1 antibody preparation
|
|
WO2020152367A1
(en)
|
2019-01-25 |
2020-07-30 |
Ospedale San Raffaele S.R.L. |
Inhibitor of dux4 and uses thereof
|
|
JP2022540638A
(ja)
*
|
2019-07-12 |
2022-09-16 |
コントラフェクト コーポレイション |
抗体を含む治療用タンパク質製剤及びその使用
|
|
TW202535466A
(zh)
*
|
2019-09-09 |
2025-09-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-il-23p19抗體調配物
|
|
GB201913697D0
(en)
|
2019-09-23 |
2019-11-06 |
King S College London |
DAP10/DAP12 fusion polypeptides
|
|
IL294461A
(en)
*
|
2020-01-13 |
2022-09-01 |
Aptevo Res & Development Llc |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
GB202003277D0
(en)
|
2020-03-06 |
2020-04-22 |
King S College London |
Therapeutic agents
|
|
BR112022022620A2
(pt)
*
|
2020-05-11 |
2022-12-20 |
Medimmune Ltd |
Formulações de anticorpos anti-il-33
|
|
CN115605185A
(zh)
*
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
|
GB202007655D0
(en)
|
2020-05-22 |
2020-07-08 |
King S College London |
Chimeric nkg2d protein
|
|
EP4171622B1
(en)
|
2021-03-23 |
2024-05-01 |
King's College London |
Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
|
|
AU2023236910A1
(en)
|
2022-03-14 |
2024-08-01 |
LamKap Bio gamma AG |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
|
GB202214120D0
(en)
|
2022-09-27 |
2022-11-09 |
King S College London |
Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
|
|
EP4389762A1
(en)
|
2022-12-23 |
2024-06-26 |
Ospedale San Raffaele S.r.l. |
Inhibitors of dux4 activity and their use in therapy.
|
|
WO2025140467A1
(zh)
*
|
2023-12-29 |
2025-07-03 |
上海复宏汉霖生物技术股份有限公司 |
稳定的高浓度抗pd-1抗体药物制剂
|
|
WO2025196207A1
(en)
|
2024-03-20 |
2025-09-25 |
King's College London |
Compositions and methods for use in depleting senescent cells and treating aging
|